Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome from Non-Controlling InterestsIncome towards Parent CompanyNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Weighted Average)Tax ProvisionsTax RateTax Rate
Others
Ratios

Gyre Therapeutics (GYRE) Interest Expenses (2020 - 2024)

Gyre Therapeutics has reported Interest Expenses over the past 9 years, most recently at $315000.0 for Q1 2024.

  • Quarterly Interest Expenses fell 51.01% to $315000.0 in Q1 2024 from the year-ago period, while the trailing twelve-month figure was $315000.0 through Dec 2024, down 51.01% year-over-year, with the annual reading at $2.6 million for FY2023, 88.79% up from the prior year.
  • Interest Expenses was $315000.0 for Q1 2024 at Gyre Therapeutics, down from $643000.0 in the prior quarter.
  • Over five years, Interest Expenses peaked at $643000.0 in Q1 2023 and troughed at $7000.0 in Q3 2020.
  • The 3-year median for Interest Expenses is $182500.0 (2020), against an average of $253750.0.
  • The largest YoY upside for Interest Expenses was 51.01% in 2024 against a maximum downside of 51.01% in 2024.
  • A 3-year view of Interest Expenses shows it stood at $50000.0 in 2020, then soared by 1186.0% to $643000.0 in 2023, then plummeted by 51.01% to $315000.0 in 2024.
  • Per Business Quant, the three most recent readings for GYRE's Interest Expenses are $315000.0 (Q1 2024), $643000.0 (Q1 2023), and $50000.0 (Q4 2020).